Is the United States Ready for Event-Driven Human Immunodeficiency Virus Preexposure Prophylaxis?

The article focuses on the daily dosing of tenofovir-emtricitabine (TDF/FTC) is the only regimen for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP). It mentions that adherence to daily dosing and discontinuation of PrEP continue to be obstacles to achieving efficacy of PrEP for some populations. It also mentions that discontinuation of daily PrEP has been noted to be a risk factor for subsequent HIV seroconversion in several studies.